CT38
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
 | This article is a stub. The talk page may contain suggestions. |
CT38 is an experimental peptide (i.e., two or more amino acids linked in a chain) that acts as an agonist for CRF2 (corticotropin-releasing factor 2).[1] CT38 is a drug developed by Cortene.[2]
Theory[edit | edit source]
Evidence[edit | edit source]
Clinicians[edit | edit source]
Lucinda Bateman is the principal investigator for a current clinical trial of CT38 for ME/CFS, it is only being tested on patients who meet both the Canadian Consensus Criteria for myalgic encephalomyelitis and the Fukuda criteria for chronic fatigue syndrome.[1]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Notable studies[edit | edit source]
Articles, talks and interviews[edit | edit source]
Learn more[edit | edit source]
- Clinical Trial to Investigate CT38 in the Treatment og Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
- Science - Hypothesis behind CT38
See also[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 Bateman, Lucinda. "Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome". clinicaltrials.gov. Retrieved March 6, 2019. Cite has empty unknown parameter:
|dead-url=(help) - ↑ 2.0 2.1 Johnson, Cort (July 14, 2018). "The Cortene Chronic Fatigue Syndrome (ME/CFS) Drug Trial Begins". Health Rising. Retrieved March 6, 2019. Cite has empty unknown parameter:
|dead-url=(help)
